Clustering-Based Method for Developing a Genomic Copy Number Alteration Signature for Predicting the Metastatic Potential of Prostate Cancer

Table 2

Cox proportional hazards model analysis of the metastatic potential score and clinical predictors.

Component	Hazard ratio	𝑃	95% CI
Univariate
MPS	2.87	0.02	1.2–7.2
Pretreatment PSA	1.00	0.04	1.0–1.1
Clinical stage T2-T3	1.27	0.70	0.4–4.2
Multivariate
MPS	2.61	0.05	1.0–6.8
Clinical stage T2-T3	0.90	0.87	0.3–3.1
Pretreatment PSA	1.00	0.18	1.0-1.0